TOKYO, May 22, 2013 /CNW/ - Ranbaxy Laboratories Limited (hereafter,
Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi
Sankyo), announced on May 22 the actions that Ranbaxy has taken in
recent years to address past conduct under prior management (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).
Daiichi Sankyo continues to support Ranbaxy in its efforts to address
and correct the conduct of the past which led to the investigations by
the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug
Administration ("USFDA"). These efforts include significant changes to
Ranbaxy's management, culture, operations and compliance.
Daiichi Sankyo believes that certain former shareholders of Ranbaxy
concealed and misrepresented critical information concerning the U.S.
DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its
available legal remedies and cannot comment further on the subject at
About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock
President and CEO: Joji Nakayama
SOURCE: Daiichi Sankyo Co., Ltd.
For further information:
Corporate Officer & Vice President
Corporate Communications Department
Daiichi Sankyo Co., Ltd.